# A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer

> **NCT01565083** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 213 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT01565083
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 213 (ACTUAL)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01565083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01565083, "A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01565083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*